Placental Nanoparticle-mediated IGF1 Gene Therapy Corrects Fetal Growth Restriction in a Guinea Pig Model

Baylea Davenport,Rebecca Wilson,Alyssa Williams,Helen Jones

DOI: https://doi.org/10.1101/2024.04.05.587765

2024-09-21

Abstract:Fetal growth restriction (FGR) caused by placental insufficiency is a major contributor to neonatal morbidity and mortality. There is currently no in utero treatment for placental insufficiency or FGR. The placenta serves as the vital communication, supply, exchange, and defense organ for the developing fetus and offers an excellent opportunity for therapeutic interventions. Here we show efficacy of repeated treatments of trophoblast-specific human insulin-like 1 growth factor (IGF1) gene therapy delivered in a non-viral, polymer nanoparticle to the placenta for the treatment of FGR. Using a guinea pig maternal nutrient restriction model (70% food intake) of FGR, nanoparticle-mediated IGF1 treatment was delivered to the placenta via ultrasound guidance across the second half of pregnancy, after establishment of FGR. This treatment resulted in correction of fetal weight in MNR + IGF1 animals compared to sham treated controls on an ad libitum diet, increased fetal blood glucose and decreased fetal blood cortisol levels compared to sham treated MNR, and showed no negative maternal side-effects. Overall, we show a therapy capable of positively impacting the entire pregnancy environment: maternal, placental, and fetal. This combined with our previous studies using this therapy at mid pregnancy in the guinea pig and in two different mouse model and three different human in vitro/ex vivo models, demonstrate the plausibility of this therapy for future human translation. Our overall goal is to improve health outcomes of neonates and decrease numerous morbidities associated with the developmental origins of disease.

Physiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the problem of fetal growth restriction (FGR), especially FGR caused by placental insufficiency. Currently, there are no effective intra - uterine treatment methods for placental insufficiency or FGR in clinical practice. As an important communication, supply, exchange and defense organ during fetal development, the placenta provides a good opportunity for therapeutic intervention. Specifically, the researchers have developed a non - viral polymeric nanoparticle for delivering human insulin - like growth factor 1 (IGF1) gene therapy specifically targeting trophoblast cells to correct FGR. By using ultrasound - guided nanoparticle - delivered IGF1 gene therapy multiple times from the second to the third trimester of pregnancy, the study aims to evaluate the long - term effects of this treatment on placental function, fetal weight and the maternal environment. The main goal of the study is to improve the health outcomes of newborns and reduce various complications associated with diseases of developmental origin. By correcting fetal growth restriction, the number of stillbirths and premature infants can be significantly reduced, as well as the risk of various diseases in adulthood, thereby achieving a healthier overall population.

Placental Nanoparticle-mediated IGF1 Gene Therapy Corrects Fetal Growth Restriction in a Guinea Pig Model

Placental hIGF1 nanoparticle gene therapy in guinea pigs ameliorates fetal growth restriction-associated changes in hepatic lipid and glucose metabolism-related signaling pathways in a fetal sex-specific manner

Maternal-fetal interfaces transcriptome changes associated with placental insufficiency and a novel gene therapy intervention

Placental treatment with insulin-like growth factor 1 via nanoparticle differentially impacts vascular remodeling factors in guinea pig sub-placenta/decidua

Mid-pregnancy placental transcriptome in a model of placental insufficiency with and without novel intervention

Anti-placental Growth Factor Antibody Ameliorates Hyperoxia-Mediated Impairment of Lung Development in Neonatal Rats

Maternal Uterine Artery Adenoviral Vascular Endothelial Growth Factor (Ad.VEGF-A165) Gene Therapy Normalises Fetal Brain Growth and Microglial Activation in Nutrient Restricted Pregnant Guinea Pigs

Nanoparticle-mediated delivery of placental gene therapy via uterine artery catheterization in a pregnant rhesus macaque

Insulin-like growth factor 1 signaling in the placenta requires endothelial nitric oxide synthase to support trophoblast function and normal fetal growth

Liposome-Encapsulated Anti-inflammatory Proteins for Targeted Delivery to the Placenta to Treat Fetal Growth Restriction

Neonatal resveratrol administration promotes skeletal muscle growth and insulin sensitivity in intrauterine growth-retarded suckling piglets associated with activation of FGF21-AMPKα pathway

Targeted Delivery of Epidermal Growth Factor to the Human Placenta to Treat Fetal Growth Restriction

Microinjection With Nanoparticles to Deliver Drugs in Prenatal Lung Explants - A Pilot Study for Prenatal Therapy in Congenital Diaphragmatic Hernia

Integrated Placental Modelling of Histology with Gene Expression to Identify Functional Impact on Fetal Growth

Transplacental Nutrient Transport Mechanisms of Intrauterine Growth Restriction in Rodent Models and Humans

Maternal Curcumin Supplementation Ameliorates Placental Function and Fetal Growth in Mice with Intrauterine Growth Retardation†

A genetically small fetus impairs placental adaptations near term

Placenta-anchored tadalafil liposomes rescues intrauterine growth restriction through continuous placental blood perfusion improvement

Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia

Maternal L-glutamine Supplementation During Late Gestation Alleviates Intrauterine Growth Restriction-Induced Intestinal Dysfunction in Piglets.